{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00523159: Phase 2 Interventional Completed Renal Cell Carcinoma
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ivicentamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:xaluritamig [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:gresonitamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03976401: Phase 2 Interventional Completed NASH - Nonalcoholic Steatohepatitis
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:pradusinstobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:peresolimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04154956: Phase 3 Interventional Active, not recruiting Non-small Cell Lung Cancer Metastatic
(2020)
Source URL:
Class:
PROTEIN
